{"id":2290,"date":"2017-07-07T18:55:00","date_gmt":"2017-07-07T22:55:00","guid":{"rendered":"https:\/\/med.sites.unc.edu\/wolberglab\/research-interests\/hemophilia\/"},"modified":"2020-07-27T15:16:04","modified_gmt":"2020-07-27T19:16:04","slug":"hemophilia","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/wolberglab\/research-interests\/hemophilia\/","title":{"rendered":"Hemophilia"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21561645\"><img loading=\"lazy\" decoding=\"async\" class=\"image-inline somoverlay alignright\" title=\"Normal and Hemophilic Clots\" src=\"https:\/\/www.med.unc.edu\/wolberglab\/wp-content\/uploads\/sites\/645\/2018\/04\/ScreenShot20170703at4.47.22PM.png\" alt=\"Normal and Hemophilic Clots\" width=\"273\" height=\"394\" \/><\/a><\/p>\n<p>Hemophilia A and B are hereditary bleeding disorders caused by deficiencies in factor VIII (FVIII) and factor IX (FIX), respectively. Hemophilia is often treated with replacement factors (ex. recombinant or plasma-derived FVIII or FIX), or bypassing agents (ex. recombinant activated factor VIIa, anti-inhibitor coagulation complex, or recombinant porcine FVIII). We have shown effects of novel hemostatic agents on fibrin formation, structure, and stability, including recombinant factor VIIa (NovoSeven) (<a class=\"external-link\" title=\"\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16351642\" target=\"_self\" rel=\"noopener noreferrer\">Wolberg et al<\/a>, <a class=\"external-link\" title=\"\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=atvb+allen+wolberg+2007\" target=\"_self\" rel=\"noopener noreferrer\">Allen et al<\/a>, <a class=\"external-link\" title=\"\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21561645\" target=\"_self\" rel=\"noopener noreferrer\">Gray et al<\/a>) and <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/jth.13887\">factor XIII<\/a>. We are continuing these investigations to understand how replacement and bypassing therapies modify fibrin quality, and identify new, improved drugs to reduce bleeding in persons with hemophilia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Hemophilia A and B are hereditary bleeding disorders caused by deficiencies in factor VIII (FVIII) and factor IX (FIX), respectively. Hemophilia is often treated with replacement factors (ex. recombinant or plasma-derived FVIII or FIX), or bypassing agents (ex. recombinant activated factor VIIa, anti-inhibitor coagulation complex, or recombinant porcine FVIII). We have shown effects of &hellip; <a href=\"https:\/\/www.med.unc.edu\/wolberglab\/research-interests\/hemophilia\/\" aria-label=\"Read more about Hemophilia\">Read more<\/a><\/p>\n","protected":false},"author":49326,"featured_media":0,"parent":2218,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-2290","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/pages\/2290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/users\/49326"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/comments?post=2290"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/pages\/2290\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/pages\/2218"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/wolberglab\/wp-json\/wp\/v2\/media?parent=2290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}